Slingshot members are tracking this event:

FDA Designates Merck's (MRK) KEYTRUDA a Breakthrough Therapy for Treatment of Microsatellite Instability High Metastatic Colorectal Cancer

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks

Slingshot Insights Explained
Catalyst Date
Occurred on:
Nov 02, 2015
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Cncr, Keytruda, Metastatic Colorectal Cancer, Pd-1 Inhibitor, Microsatellite Instability High